A New Category of Breast Cancer Means New Possibilities
At the American Society for Clinical Oncology (ASCO) conference earlier this year, a new breast cancer drug received a standing ovation after researchers announced the results of their trial. This drug is Enhertu, and it was recently approved by the FDA to treat people with a certain type of metastatic breast cancer. VBCF doesn’t tend to report on specific drugs for breast cancer treatment because treatment is so individualized – one treatment that works wonders for one person could be ineffective for another. The reason Enhertu warrants some discussion is that it essentially creates a new type of breast cancer that can be a new research focus: HER2-low.
Recent Comments